But the administrator of the Centers for Medicare & Medicaid Services (CMS), Mehmet Oz, MD, said in a post on the social ...
Data from the 52-week follow-up of the phase III MINT trial of inebilizumab (Uplizna) in generalized myasthenia gravis was presented at the American Association of Neuromuscular & Electrodiagnostic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback